title: Direct-to-consumer genetic testing: Perspectives on its value in healthcare.
abstract: The direct-to-consumer genetic testing debate reached a fever pitch in November 2013 when the US Food and Drug Administration (FDA) instructed 23andMe to discontinue marketing and sale of their Personal Genome Service. In 2015, 23andMe emerged with FDA approval to market a carrier test for Bloom syndrome only, and plans to release additional reports. The dust has settled and it is time to ask: What have we learned, and where do we go from here?
authors.affiliation: Coriell Institute for Medical Research, Camden, New Jersey, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Delaney
authors.affiliation: Coriell Institute for Medical Research, Camden, New Jersey, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Christman
mesh_terms: D022126:Access to Information; D001816:Bloom Syndrome / Q000175:diagnosis / Q000235:genetics; D003695:Delivery of Health Care / Q000639:trends*; D000067108:Direct-To-Consumer Screening and Testing / Q000639:trends*; D005820:Genetic Testing / Q000639:trends*; D016678:Genome; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration